Cancer Advocacy Group Backs State Legislation Enhancing Diversity in Clinical Trials
Cancer Advocates Urge the Senate to Follow the House’s Lead Ensuring More Diversity in Clinical Trials.
Denise Billings
Ninth Annual Research Breakfast Brings Cancer Experts Together to Discuss Current State of Clinical Trials
Leaders in Cancer Community Explore Potential Opportunities to Overcome Barriers
October 9, 2018
North Carolina’s three NCI-Designated Cancer Centers, UNC Lineberger Comprehensive Cancer Center, Duke Cancer Institute, and Wake Forest Baptist Medical Comprehensive Cancer Centers served as the honorary hosts for the Research Breakfast.
“Today’s breakfast is just one of five clinical trial forums being held across the country that are focusing on ACS CAN’s Report: Barriers to Patient Enrollment in Therapeutic Clinical Trials for Cancer,” said Christine Weason, ACS CAN North Carolina government relations director. “We convened key thought leaders and subject matter experts from the cancer community to gain foundational insight to the barriers identified in the report and to explore potential opportunities and promising practices that may alleviate the barriers patients confront in enrolling and participating in clinical trials.”
Hoping to improve patient enrollment, ACS CAN and 14 other organizations from all sectors of the cancer research community including patient advocacy groups, provider groups, cancer institutions, and the drug research and development industry, developed a set of consensus recommendations detailed in the report. Examples include making the discussion of specific trial options a more regular part of the doctor-patient treatment decision, increasing funding for trial-support personnel to help patients understand, enroll and manage their trial, and helping patients with added costs that occasionally result from trial participation such as travel, parking, and housing.
While many initiatives have been launched to tackle barriers to cancer clinical trial enrollment, they tend to focus on a subset of the overall barriers. For example, patient education and decision making are often the focus of efforts to increase participation, yet other structural and clinical factors like the lack of locally available clinical trials matching a patient’s characteristics or lack of interest on the part of providers to recommend clinical trials as an option for up to 75 percent of their patients.
“Barriers to entry in clinical trials are a real problem. We have halay conversations daily about the need to make clinical research a standard healthcare option instead of something that physicians and cancer patients view as a ‘Hail Mary’ care approach.,” said Brendan Early, vice president of clinical development for PRA Health Sciences. “This problem is multifactorial, with varying views. Today’s forum was a very effective opportunity to look at the issue from all sides.”
The objective of cancer research is to generate new knowledge that can be used to save lives and protect quality of life for patients with cancer. Clinical trials are a key step in that process and yet, only a small fraction of patients end up enrolling in a cancer clinical trial because of barriers that make participation difficult or even impossible. As a result, approximately 20 percent of cancer clinical trials fail due to insufficient patient enrollment.
The event included a panel discussion on understanding and addressing barriers. Panelists included with Shelton Earp, MD, director, UNC Lineberger Comprehensive Cancer Center, Michael Kastan, MD, PhD, executive director, Duke Cancer Institute, Karen Winkfield, MD, PhD, associate director for office of cancer health equity, Wake Forest Baptist Medical Comprehensive Cancer Center, Greg Licholai, MD, MBA, chief medical information officer, PRA Health Sciences, Jean Sellers, RN, MSN, administrative clinical director, UNC Lineberger, and The Honorable Gregory Murphy, MD, NC State Representative, District 9.
“We at ACS CAN hope today’s research breakfast will raise awareness in our elected officials of the importance clinical trials play in our healthcare system,” said Weason. “We encourage continued dialogue between the public and private sectors with the aim of implementing evidence-based initiatives to eliminate the barriers cancer patients face when seeking innovative clinical trial treatments.”
This year, the American Cancer Society estimates that 55,130 people in North Carolina will be diagnosed with cancer and 20,380 will die from the disease.
ACS CAN, the nonprofit, nonpartisan advocacy affiliate of the American Cancer Society, supports evidence-based policy and legislative solutions designed to eliminate cancer as a major health problem. ACS CAN works to encourage elected officials and candidates to make cancer a top national priority. ACS CAN gives ordinary people extraordinary power to fight cancer with the training and tools they need to make their voices heard. For more information, visit https://www.fightcancer.org/.
More Press Releases About